Minnelide: a possible new drug for the treatment of CRPC?

According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …

Another research team, and another micro-RNA …

Last week we mentioned that one specific form of micro-ribonucleic acid (miRNA) may be usable in the development of a drug or drugs to stop the process of metastasis in men with high-risk forms of prostate cancer. Another recent study goes one step further than that. … READ MORE …

Iodine-131-MIP-1095, a new radiopharmaceutical, in clinical trials at MSKCC

There are few radiopharmaceuticals in clinical trials in the US (although there are several in use in Germany), so when a new one is announced, we take notice. … READ MORE …

“Competitive analysis” in the development of drugs for advanced prostate cancer

So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …

Stopping metastasis before it even begins … Can we do that?

The idea that one could stop the initiation of prostate cancer metastasis before it even starts is fundamental to the idea that we might be able to eliminate prostate cancer as a cause of death. And it’s as true for prostate cancer as it is for nearly every other form of cancer. The problem is that we don’t yet know why prostate cancer metastasizes … and many suspect there may be more than one reason. … READ MORE …

Another new owner for Provenge

According to a media release issued rather quietly a week ago, a large Chinese conglomerate has now bought Provenge (sipuleucel-T) from Valeant, which had acquired it when Valeant bought Dendreon. … READ MORE …

A possible new opportunity for treatment of advanced, neuroendocrine forms of prostate cancer?

An article by Strosberg et al. in today’s issue of the New England Journal of Medicine has nothing to do with prostate cancer at all; it’s all about a new form of treatment for certain types of advanced midgut cancer — but … READ MORE …